Please login to the form below

Not currently logged in
Email:
Password:

morphosys

This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

Additional competition is however looming from MorphoSys and Takeda, which each have anti-CD38 drugs in pivotal-stage testing for myeloma, while another rival is Bristol-Myers Squibb and AbbVie’s

Latest news

  • GSK pushes rheumatoid arthritis antibody into phase 3 GSK pushes rheumatoid arthritis antibody into phase 3

    GSK acquired the rights to otilimab from MorphoSys in a 445m deal agreed in 2013, and the German biotech stands to a receive a 22m milestone payment with the start of

  • MorphoSys eyes 2020 launch for lymphoma CAR-T challenger MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

    New trial data has set up a US filing later this year for MorphoSys’ anti-CD19 antibody tafasitamab (MOR208) – and a possible challenge to Novartis and Gilead’s CAR-T therapies. ... The L-MIND data raise the likelihood of MorphoSys attracting a

  • Janssen looks to expand Darzalex in Europe Janssen looks to expand Darzalex in Europe

    Additionally, both MorphoSys and Takeda each have their own myeloma drugs in mid-stage testing and Bristol-Myers Squibb and AbbVie are hoping that SLAMF7 targeting Empliciti, in combination with Revlimid,

  • Sanofi's Darzalex rival scores in myeloma trial Sanofi's Darzalex rival scores in myeloma trial

    In the meantime, additional anti-CD38 competition is looming from the likes of MorphoSys with MOR202 and Takeda with TAK-079, both in mid-stage testing, while J&J and Genmab

  • Morphosys’ Darzalex patent challenge hits a hurdle Morphosys’ Darzalex patent challenge hits a hurdle

    In a statement, Morphosys said it was disappointed by the outcome but is considering its options and may launch an appeal. ... Morphosys insists that the court decision has “no bearing” on its patents for MOR202 and its ability to develop the

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.

  • Pharma deals in March 2015 Pharma deals in March 2015

    In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during August 2014 Pharma deals during August 2014

    These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.

  • Pharma deals during June 2014 Pharma deals during June 2014

    Joining the checkpoint modulator fray, Merck Serono formed a partnership with Morphosys to discover and develop antibodies against certain immune checkpoints using the Morphosys Ylanthia platform.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics